{"id":91614,"date":"2023-10-27T20:18:00","date_gmt":"2023-10-27T12:18:00","guid":{"rendered":"https:\/\/gothe.tw\/?p=91614"},"modified":"2023-10-27T20:18:00","modified_gmt":"2023-10-27T12:18:00","slug":"%e6%bd%9b%e5%9c%a8fic-bic-%e5%be%a9%e5%ae%8f%e6%bc%a2%e9%9c%96%e5%85%a9%e6%ac%beadc%e5%89%b5%e6%96%b0%e8%97%a5%e5%90%8c%e6%99%82%e7%8d%b2%e6%89%b9%e8%87%a8%e5%ba%8a","status":"publish","type":"post","link":"https:\/\/gothe.tw\/?p=91614","title":{"rendered":"\u6f5b\u5728FIC\/BIC \u5fa9\u5b8f\u6f22\u9716\u5169\u6b3eADC\u5275\u65b0\u85e5\u540c\u6642\u7372\u6279\u81e8\u5e8a"},"content":{"rendered":"<div>\n<div>\n<p><span class=\"legendSpanClass\">\u4e0a\u6d77<\/span><span class=\"legendSpanClass\">2023\u5e7410\u670827\u65e5<\/span> \/\u7f8e\u901a\u793e\/ \u2014 2023\u5e7410\u670827\u65e5\uff0c\u5fa9\u5b8f\u6f22\u9716\uff082696.HK\uff09\u5ba3\u5e03\uff0c\u57fa\u65bc\u8207\u5b9c\u806f\u751f\u7269\u7684\u5408\u4f5c\uff0c\u516c\u53f8\u958b\u767c\u7684\u5169\u6b3e\u6297\u9ad4\u5076\u806f\u85e5\u7269\uff08antibody-drug-conjugate, ADC\uff09\u2014\u2014\u9776\u5411\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\uff08EGFR\uff09\u7684\u65b0\u578bADC\u5019\u9078\u85e5\u7269\u8a3b\u5c04\u7528HLX42\uff0c\u53ca\u9776\u5411\u7a0b\u5e8f\u6027\u6b7b\u4ea1-\u914d\u9ad41\uff08PD-L1\uff09\u7684\u65b0\u578bADC\u5019\u9078\u85e5\u7269\u8a3b\u5c04\u7528HLX43\uff0c\u5df2\u7d93\u540c\u6b65\u7372\u5f97\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u81e8\u5e8a\u8a66\u9a57\u6279\u6e96\uff0c\u64ec\u7528\u65bc\u665a\u671f\/\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u7684\u6cbb\u7642\u3002\u9019\u662f\u5fa9\u5b8f\u6f22\u9716\u9996\u6279\u6b65\u5165\u81e8\u5e8a\u958b\u767c\u968e\u6bb5\u7684ADC\u5275\u65b0\u85e5\u3002\u76ee\u524d\u91dd\u5c0dPD-L1\u9776\u9ede\u958b\u767c\u7684ADC\u7522\u54c1\u8f03\u5c11\uff0cHLX43\u662f\u570b\u5167\u9996\u500b\u9032\u5165\u81e8\u5e8a\u968e\u6bb5\u7684\u9776\u5411PD-L1\u7684 ADC\u7522\u54c1\u3002\u6b64\u5916\uff0c\u516c\u53f8\u7ba1\u7dda\u4e2d\u591a\u6b3eADC\/AXC\u5019\u9078\u85e5\u7269\u6b63\u8655\u65bc\u81e8\u5e8a\u524d\u958b\u767c\u968e\u6bb5\u3002<\/p>\n<p><b>EGFR\u9776\u5411ADC\u5019\u9078\u85e5HLX42<\/b><\/p>\n<p>EGFR\u5c6c\u65bc\u53d7\u9ad4\u916a\u6c28\u9178\u6fc0\u9176\uff0c\u5728\u7d30\u80de\u589e\u6b96\u3001\u5206\u5316\u548c\u9077\u79fb\u7684\u904e\u7a0b\u4e2d\u767c\u63ee\u91cd\u8981\u4f5c\u7528\u3002\u7814\u7a76\u767c\u73fe\uff0c\u8207\u6b63\u5e38\u7d44\u7e54\u76f8\u6bd4\uff0cEGFR\u7684\u7a81\u8b8a\u6216\u8005\u9ad8\u8868\u9054\u8207\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u3001\u7d50\u8178\u764c\u7b49\u816b\u7624\u7684\u767c\u751f\u5bc6\u5207\u76f8\u95dc\uff0c\u662f\u6297\u816b\u7624\u85e5\u7269\u958b\u767c\u4e2d\u7684\u91cd\u8981\u9776\u9ede<sup>[1]<\/sup>\u3002\u76e1\u7ba1\u591a\u6b3eEGFR\u6297\u9ad4\u548c\u7b2c\u4e09\u4ee3EGFR\u53d7\u9ad4\u916a\u6c28\u9178\u6fc0\u9176\u6291\u88fd\u5291\uff08TKI\uff09\u5df2\u7d93\u5728\u816b\u7624\u6cbb\u7642\u4e2d\u7372\u5f97\u4e86\u5ee3\u6cdb\u6210\u529f\uff0c\u4f46\u5c0d\u65bc\u56e0\u8010\u85e5\u800c\u5c0e\u81f4\u7684\u6a19\u6e96\u6cbb\u7642\u5931\u6557\u6216\u6cbb\u7642\u5f8c\u5fa9\u767c\u7684\u816b\u7624\u60a3\u8005\uff0c\u4ecd\u5b58\u5728\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42<sup>[2]<\/sup>\u3002\u8fd1\u5e74\u4f86\uff0c\u96a8\u8457ADC\u6280\u8853\u7684\u5feb\u901f\u767c\u5c55\uff0cADC\u85e5\u7269\u7684\u958b\u767c\u70ba\u816b\u7624\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7642\u65b9\u6848<sup>[3]<\/sup>\uff0c\u9776\u5411EGFR\u7684ADC\u85e5\u7269\u6709\u671b\u514b\u670d\u73fe\u6709\u9776\u5411EGFR\u6cbb\u7642\u7684\u8010\u85e5\u6a5f\u88fd\uff0c\u70ba\u66f4\u591a\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u3001\u7d50\u76f4\u8178\u764c\u7b49\u60a3\u8005\u5e36\u4f86\u81e8\u5e8a\u7372\u76ca\u3002<\/p>\n<p>HLX42\u7531\u9ad8\u5ea6\u7279\u7570\u6027\u7684\u4eba\u6e90\u5316lgG1 EGFR\u6297\u9ad4\u5206\u5b50\u3001\u53ef\u88c2\u89e3\u7684\u65b0\u578b\u9023\u63a5\u5b50-\u8377\u8f09\u6bd2\u7d20\u5076\u806f\u88fd\u5099\u800c\u6210\uff0c\u5176\u85e5\u7269\u6297\u9ad4\u6bd4\uff08drug-to-antibody ratio, DAR\uff09\u7d04\u70ba8\u3002\u5176\u4e2d\uff0cHLX42\u7684\u8377\u8f09\u6bd2\u7d20\u70ba\u4e00\u7a2e\u65b0\u578bDNA\u62d3\u64b2\u7570\u69cb\u9176I\uff08Topoisomerase I\uff09\u5c0f\u5206\u5b50\u6291\u88fd\u5291\uff0c\u901a\u904e\u9020\u6210DNA\u96d9\u93c8\u65b7\u88c2\uff0c\u963b\u65b7DNA\u5fa9\u88fd\uff0c\u5f9e\u800c\u5c0e\u81f4\u816b\u7624\u7d30\u80de\u96d5\u4ea1\u3002\u975c\u8108\u8f38\u8a3b\u5f8c\uff0cHLX42\u7684\u9023\u63a5\u5b50-\u6bd2\u7d20\u80fd\u5920\u5728\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u7279\u7570\u6027\u88c2\u89e3\u91cb\u653e\uff0c\u5177\u5099\u8f03\u5f37\u7684\u65c1\u89c0\u8005\u6bba\u50b7\u6548\u61c9\uff0c\u7368\u7279\u7684\u4f5c\u7528\u6a5f\u88fd\u4f7f\u5f97HLX42\u8f03\u540c\u985eADC\u7522\u54c1\u5177\u6709\u66f4\u5927\u7684\u6cbb\u7642\u7a97\u53e3\uff0c\u589e\u5f37ADC\u5728\u5be6\u9ad4\u816b\u7624\u4e2d\u7684\u6cbb\u7642\u6548\u679c\u3002<\/p>\n<p><b>PD-L1\u9776\u5411ADC\u5019\u9078\u85e5HLX43<\/b><\/p>\n<p>\u7a0b\u5e8f\u6027\u6b7b\u4ea1-\u914d\u9ad41\uff08PD-L1\uff09\u662f\u4e00\u985e\u8de8\u819c\u86cb\u767d\uff0c\u662f\u514d\u75ab\u53cd\u61c9\u4e2d\u91cd\u8981\u7684\u8ca0\u6027\u8abf\u63a7\u56e0\u5b50\uff0c\u53ef\u901a\u904e\u8207\u7a0b\u5e8f\u6b7b\u4ea1\u53d7\u9ad41\uff08PD-1\uff09\u7d50\u5408\u555f\u52d5T\u7d30\u80de\u7a0b\u5e8f\u6027\u6b7b\u4ea1\uff0c\u4f7f\u816b\u7624\u7d30\u80de\u7372\u5f97\u514d\u75ab\u9003\u9038<sup>[4]<\/sup>\u3002\u8fd1\u5e74\u4f86\u4ee5\u6297PD-1\/L1\u6297\u9ad4\u70ba\u4ee3\u8868\u7684\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u88fd\u5291\u4fc3\u9032\u4e86\u816b\u7624\u514d\u75ab\u6cbb\u7642\u7684\u9ad8\u901f\u767c\u5c55\uff0c\u6210\u70ba\u816b\u7624\u60a3\u8005\u5404\u7dda\u6cbb\u7642\u7684\u4e3b\u8981\u624b\u6bb5\u4e4b\u4e00\u3002\u7136\u800c\uff0c\u90e8\u5206PD-L1\u967d\u6027\u60a3\u8005\u5c0d\u8a72\u7642\u6cd5\u7121\u97ff\u61c9\uff0c\u6216\u8005\u51fa\u73fe\u8010\u85e5<sup>[5]<\/sup>\u3002\u9452\u65bcPD-L1\u5728\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u3001\u7d50\u76f4\u8178\u764c\u3001\u4e09\u9670\u6027\u4e73\u817a\u764c\u3001\u9c57\u72c0\u7d30\u80de\u764c\u7b49\u591a\u7a2e\u764c\u7a2e\u4e2d\u5747\u6709\u8868\u9054\uff0c\u4e14\u5728\u6b63\u5e38\u7d44\u7e54\u4e2d\u7684\u8868\u9054\u6709\u9650\uff0c\u56e0\u6b64PD-L1\u5728\u4f5c\u70ba\u514d\u75ab\u6aa2\u67e5\u9ede\u4e4b\u5916\uff0c\u9084\u5177\u5099\u958b\u767cPD-L1\u9776\u5411ADC\u85e5\u7269\u7684\u6f5b\u529b\uff0c\u6709\u671b\u70ba\u7121\u6cd5\u5f9ePD-1\/L1\u514d\u75ab\u6cbb\u7642\u4e2d\u7372\u76ca\u7684\u60a3\u8005\u5e36\u4f86\u6709\u6548\u7684\u6cbb\u7642\u65b9\u6848<sup>[6]<\/sup>\u3002<\/p>\n<p>HLX43\u7531\u9ad8\u5ea6\u7279\u7570\u6027\u7684\u4eba\u6e90\u5316lgG1 PD-L1\u6297\u9ad4\u5206\u5b50\u3001\u53ef\u88c2\u89e3\u7684\u65b0\u578b\u9023\u63a5\u5b50-\u8377\u8f09\u6bd2\u7d20\u5076\u806f\u88fd\u5099\u800c\u6210\uff0c\u5176\u85e5\u7269\u6297\u9ad4\u6bd4\uff08drug-to-antibody ratio, DAR\uff09\u7d04\u70ba8\u3002\u5176\u4e2d\uff0cHLX43\u7684\u8377\u8f09\u6bd2\u7d20\u70ba\u4e00\u7a2e\u65b0\u578bDNA\u62d3\u64b2\u7570\u69cb\u9176I\uff08Topoisomerase I\uff09\u5c0f\u5206\u5b50\u6291\u88fd\u5291\uff0c\u901a\u904e\u9020\u6210DNA\u96d9\u93c8\u65b7\u88c2\uff0c\u963b\u65b7DNA\u5fa9\u88fd\uff0c\u5f9e\u800c\u5c0e\u81f4\u816b\u7624\u7d30\u80de\u96d5\u4ea1\u3002\u975c\u8108\u8f38\u8a3b\u5f8c\uff0cHLX43\u7684\u9023\u63a5\u5b50-\u6bd2\u7d20\u80fd\u5920\u5728\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u7279\u7570\u6027\u88c2\u89e3\u91cb\u653e\uff0c\u5177\u5099\u8f03\u5f37\u7684\u65c1\u89c0\u8005\u6bba\u50b7\u6548\u61c9\uff0c\u7368\u7279\u7684\u4f5c\u7528\u6a5f\u88fd\u4f7f\u5f97HLX43\u8f03\u540c\u985eADC\u7522\u54c1\u5177\u6709\u66f4\u5927\u7684\u6cbb\u7642\u7a97\u53e3\uff0c\u589e\u5f37ADC\u5728\u5be6\u9ad4\u816b\u7624\u4e2d\u7684\u6cbb\u7642\u6548\u679c\u3002<\/p>\n<p>\u517c\u5177\u6297\u9ad4\u5206\u5b50\u7684\u9ad8\u5ea6\u9776\u5411\u6027\u548c\u7d30\u80de\u6bd2\u7d20\u7684\u5f37\u5927\u6bba\u50b7\u529b\uff0cHLX42\u3001HLX43\u5df2\u7d93\u5728\u975e\u81e8\u5e8a\u85e5\u7406\u5b78\u7814\u7a76\u3001\u85e5\u4ee3\u52d5\u529b\u5b78\u7814\u7a76\u53ca\u5b89\u5168\u6027\u8a55\u50f9\u4e2d\u5c55\u73fe\u51fa\u826f\u597d\u7684\u6297\u816b\u7624\u6d3b\u6027\u548c\u5b89\u5168\u6027\u3002\u5728\u7b2c\u4e09\u4ee3EGFR TKI\uff08\u5967\u5e0c\u66ff\u5c3c\uff09\u6216EGFR\u55ae\u514b\u9686\u6297\u9ad4\uff08\u897f\u59a5\u6614\u55ae\u6297\uff09\u8010\u85e5\u7684\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u53ca\u7d50\u76f4\u8178\u764c\u816b\u7624\u6a21\u578b\u4e2d\uff0cHLX42\u986f\u793a\u51fa\u816b\u7624\u6bba\u50b7\u6548\u679c\u3002\u5728\u6297PD-1\u55ae\u6297\u8010\u85e5\u7684\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u3001\u7d50\u76f4\u8178\u764c\u3001\u4e09\u9670\u6027\u4e73\u817a\u764c\u3001\u9c57\u72c0\u7d30\u80de\u764c\u7b49\u816b\u7624\u6a21\u578b\u4e2d\uff0cHLX43\u986f\u793a\u51fa\u826f\u597d\u7684\u816b\u7624\u6bba\u50b7\u6548\u679c\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0cHLX42\u53caHLX43\u7684\u81e8\u5e8a\u524d\u7814\u7a76\u6578\u64da\u540c\u6b65\u5165\u9078\u4e862023\u6b50\u6d32\u816b\u7624\u5167\u79d1\u5b78\u6703\uff08ESMO\uff09\u5927\u6703\uff0c\u4ee5\u58c1\u5831\u5f62\u5f0f\u9032\u884c\u5c55\u793a\u3002\u5fa9\u5b8f\u6f22\u9716\u4e5f\u8a08\u5283\u555f\u52d5\u76f8\u61c9\u7684I\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u4ee5\u8a55\u4f30HLX42\/HLX43\u5728\u665a\u671f\/\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u53ca\u85e5\u4ee3\u52d5\u529b\u5b78\u7279\u5f81\u3002<\/p>\n<p>\u672a\u4f86\uff0c\u5fa9\u5b8f\u6f22\u9716\u5c07\u6301\u7e8c\u7acb\u8db3\u65bc\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\uff0c\u5145\u5206\u767c\u63ee\u516c\u53f8\u5728\u6297\u9ad4\u85e5\u7269\u548c\u6297\u9ad4\u5076\u806f\u85e5\u7269\u9818\u57df\u7684\u4e00\u9ad4\u5316\u5e73\u81fa\u512a\u52e2\uff0c\u7a4d\u6975\u63a2\u7d22\u65b0\u9776\u9ede\u3001\u65b0\u6a5f\u88fd\uff0c\u4e0d\u65b7\u62d3\u5c55\u75be\u75c5\u9818\u57df\u548c\u65b0\u5206\u5b50\u985e\u578b\uff0c\u70ba\u5168\u7403\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u9ad8\u8cea\u91cf\u3001\u53ef\u8ca0\u64d4\u7684\u5275\u65b0\u6cbb\u7642\u65b9\u6848\u3002<\/p>\n<p><b>\u95dc\u65bc\u5fa9\u5b8f\u6f22\u9716<\/b><\/p>\n<p>\u5fa9\u5b8f\u6f22\u9716\uff082696.HK\uff09\u662f\u4e00\u5bb6\u570b\u969b\u5316\u7684\u5275\u65b0\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u70ba\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u53ef\u8ca0\u64d4\u7684\u9ad8\u54c1\u8cea\u751f\u7269\u85e5\uff0c\u7522\u54c1\u8986\u84cb\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u75be\u75c5\u3001\u773c\u79d1\u75be\u75c5\u7b49\u9818\u57df\uff0c\u5df2\u5728\u4e2d\u570b\u4e0a\u5e025\u6b3e\u7522\u54c1\uff0c\u5728\u570b\u969b\u4e0a\u5e021\u6b3e\u7522\u54c1\uff0c19\u9805\u9069\u61c9\u7665\u7372\u6279\uff0c2\u500b\u4e0a\u5e02\u7533\u8acb\u5206\u5225\u7372\u7f8e\u570bFDA\u548c\u6b50\u76dfEMA\u53d7\u7406\u3002\u81ea2010\u5e74\u6210\u7acb\u4ee5\u4f86\uff0c\u5fa9\u5b8f\u6f22\u9716\u5df2\u5efa\u6210\u4e00\u9ad4\u5316\u751f\u7269\u88fd\u85e5\u5e73\u81fa\uff0c\u9ad8\u6548\u53ca\u5275\u65b0\u7684\u81ea\u4e3b\u6838\u5fc3\u80fd\u529b\u8cab\u7a7f\u7814\u767c\u3001\u751f\u7522\u53ca\u5546\u696d\u904b\u71df\u5168\u7522\u696d\u93c8\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u5b8c\u5584\u9ad8\u6548\u7684\u5168\u7403\u5275\u65b0\u4e2d\u5fc3\uff0c\u6309\u7167\u570b\u969b\u85e5\u54c1\u751f\u7522\u8cea\u91cf\u7ba1\u7406\u898f\u7bc4\uff08GMP\uff09\u6a19\u6e96\u9032\u884c\u751f\u7522\u548c\u8cea\u91cf\u7ba1\u63a7\uff0c\u4e0d\u65b7\u592f\u5be6\u4e00\u9ad4\u5316\u7d9c\u5408\u751f\u7522\u5e73\u81fa\uff0c\u5176\u4e2d\uff0c\u4e0a\u6d77\u5f90\u532f\u57fa\u5730\u5df2\u7372\u5f97\u4e2d\u570b\u548c\u6b50\u76dfGMP\u8a8d\u8b49\uff0c\u677e\u6c5f\u57fa\u5730\uff08\u4e00\uff09\u4e5f\u5df2\u7372\u5f97\u4e2d\u570bGMP\u8a8d\u8b49\u3002<\/p>\n<p>\u5fa9\u5b8f\u6f22\u9716\u524d\u77bb\u6027\u5e03\u5c40\u4e86\u4e00\u500b\u591a\u5143\u5316\u3001\u9ad8\u8cea\u91cf\u7684\u7522\u54c1\u7ba1\u7dda\uff0c\u6db5\u84cb20\u591a\u7a2e\u5275\u65b0\u55ae\u514b\u9686\u6297\u9ad4\uff0c\u4e26\u5168\u9762\u63a8\u9032\u57fa\u65bc\u81ea\u6709\u6297PD-1\u55ae\u6297H\u85e5 \u6f22\u65af\u72c0\u00ae\u7684\u816b\u7624\u514d\u75ab\u806f\u5408\u7642\u6cd5\u3002\u7e7c\u570b\u5167\u9996\u500b\u751f\u7269\u985e\u4f3c\u85e5\u6f22\u5229\u5eb7\u00ae\uff08\u5229\u59a5\u6614\u55ae\u6297\uff09\u3001\u4e2d\u570b\u9996\u500b\u81ea\u4e3b\u7814\u767c\u7684\u4e2d\u6b50\u96d9\u6279\u55ae\u6297\u85e5\u7269\u6f22\u66f2\u512a\u00ae\uff08\u66f2\u59a5\u73e0\u55ae\u6297\uff0c\u6b50\u6d32\u5546\u54c1\u540d\uff1aZercepac\u00ae\uff0c\u6fb3\u5927\u5229\u4e9e\u5546\u54c1\u540d\uff1aTuzucip\u00ae\u548cTrastucip\u00ae\uff09\u3001\u6f22\u9054\u9060\u00ae\uff08\u963f\u9054\u6728\u55ae\u6297\uff09\u548c\u6f22\u8c9d\u6cf0\u00ae\uff08\u8c9d\u4f10\u73e0\u55ae\u6297\uff09\u76f8\u7e7c\u7372\u6279\u4e0a\u5e02\uff0c\u5275\u65b0\u7522\u54c1\u6f22\u65af\u72c0\u00ae\uff08\u65af\u9b6f\u5229\u55ae\u6297\uff09\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u5fae\u885b\u661f\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\uff08MSI-H\uff09\u5be6\u9ad4\u7624\u3001\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u3001\u5ee3\u6cdb\u671f\u5c0f\u7d30\u80de\u80ba\u764c\u548c\u98df\u7ba1\u9c57\u72c0\u7d30\u80de\u764c\uff0c\u4e26\u6210\u70ba\u5168\u7403\u9996\u500b\u7372\u6279\u4e00\u7dda\u6cbb\u7642\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6297PD-1\u55ae\u6297\u3002\u516c\u53f8\u4ea6\u540c\u6b65\u5c3116\u500b\u7522\u54c1\u5728\u5168\u7403\u7bc4\u570d\u5167\u958b\u5c5530\u591a\u9805\u81e8\u5e8a\u8a66\u9a57\uff0c\u5c0d\u5916\u6388\u6b0a\u5168\u9762\u8986\u84cb\u6b50\u7f8e\u4e3b\u6d41\u751f\u7269\u85e5\u5e02\u5834\u548c\u773e\u591a\u65b0\u8208\u5e02\u5834\u3002<\/p>\n<p><b>\u53c3\u8003\u6587\u737b<\/b><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[1] Ni cholson, Robert Ian, Julia Margaret Wendy Gee, and Maureen Elaine Harper. EGFR and cancer prognosis. European journal of cancer 37 (2001): 9-15.\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[2] Tan, Chee Seng, D. Gilligan, and S. Pacey. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. The Lancet Oncology 16.9(2015): e447-59.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[3] Ponziani S, Di Vittorio G, Pitari G, et al. Antibody-Drug Conjugates: The New Frontier of Chemotherapy. Int J Mol Sci. 2020 Jul 31;21(15):5510.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[4] Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer[J]. American Journal of Cancer Research, 2020, 10(3):727-742.\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[5] Attili I, Tarantino P, Passaro A, et al. Strategies to overcome resistance to immune checkpoint blockade in lung cancer[J]. Lung cancer: Journal of the International Association for the Study of Lung Cancer, 2021(154-):154.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[6] Kwan B, Ramirez M, Jin S, et al. 783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors[J]. 2021.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\u00a0<\/p>\n<\/div>\n<p>\n\u65b0\u805e\u4f86\u6e90\uff1aPR Newswire<\/p>\n<p>\u4ee5\u4e0a\u65b0\u805e\u6295\u7a3f\u5167\u5bb9\u7531PR Newswire \u7f8e\u901a\u793e\u5168\u6b0a\u81ea\u8ca0\u8cac\u4efb\uff0c\u82e5\u6709\u6d89\u53ca\u4efb\u4f55\u9055\u53cd\u6cd5\u4ee4\u3001\u9055\u53cd\u672c\u7db2\u7ad9\u6703\u54e1\u689d\u6b3e\u3001\u6709\u4fb5\u5bb3\u7b2c\u4e09\u4eba\u6b0a\u76ca\u4e4b\u865e\uff0c\u5c07\u4e00\u6982\u7531PR Newswire \u7f8e\u901a\u793e\u627f\u64d4\u6cd5\u5f8b\u53ca\u640d\u5bb3\u8ce0\u511f\u4e4b\u8cac\u4efb\uff0c\u8207\u65b0\u982d\u689dThehubnews\u7121\u95dc\u3002<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u4e0a\u6d772023\u5e7410\u670827\u65e5 \/\u7f8e\u901a\u793e\/ \u2014 <\/p>\n","protected":false},"author":6,"featured_media":91615,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[423],"class_list":["post-91614","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life","tag-423","two-columns"],"_links":{"self":[{"href":"https:\/\/gothe.tw\/index.php?rest_route=\/wp\/v2\/posts\/91614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gothe.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gothe.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gothe.tw\/index.php?rest_route=\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/gothe.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=91614"}],"version-history":[{"count":0,"href":"https:\/\/gothe.tw\/index.php?rest_route=\/wp\/v2\/posts\/91614\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gothe.tw\/index.php?rest_route=\/wp\/v2\/media\/91615"}],"wp:attachment":[{"href":"https:\/\/gothe.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=91614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gothe.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=91614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gothe.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=91614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}